FibroBiologics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
21.9%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$4.01next fiscal year
Monitoring Framework
Key Performance Indicators
CYWC628 Phase 1/2 Trial Patient Enrollment Quarterly2.0Target: 120 patients
Quarterly Cash Burn Rate Quarterly5MTarget: Minimize discretionary spending to preserve capital
Total Issued and Pending Patents Annually270.0Target: Continuous expansion of IP portfolio
Watch Items
- CYWC628 Phase 1/2 Diabetic Foot Ulcer Trial Interim DataTrigger: Interim 6-week safety and efficacy analysis of a predefined participant cohortAction: Evaluate clinical efficacy signals and safety parameters to support subsequent Phase 3 planning and potential licensing discussions.
- FDA IND Clearance for CYPS317 (Psoriasis)Trigger: FDA response to the updated IND submissionAction: Initiate clinical site onboarding and preparation for Phase 1/2 trial dosing in psoriasis patients upon clearance.
- FDA IND Submission for CYMS101 (Multiple Sclerosis)Trigger: Filing of the IND application in the second half of 2026Action: Prepare clinical protocols and finalize manufacturing batches to support immediate trial initiation post-clearance.
- Nasdaq Continued Listing ComplianceTrigger: Maintaining minimum bid price and public float requirementsAction: Monitor stock price performance and execute capital management strategies to prevent future delisting notices.
Research as of 20 Jun 2026